VANCOUVER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce that it will be reporting its financial results for the year ended December 31, 2025 (“Q4 2025”) after market close on Monday, March 23, 2026. The Company will be hosting a conference call to discuss Q4 2025 results on Tuesday, March 24, 2026. Conference call details are as follows:Time: 7:00 AM PT / 10:00 AM ETConference ID: 68562Local dial-in:         (+1) 289 514 5100Toll Free N. America: (+1) 800 717 1738Webcast: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=2A9CD702-2774-4357-AB08-7BF1F20DC002    ABOUT...

NINGDE, China, March 09, 2026 (GLOBE NEWSWIRE) — Oriental Rise Holdings Limited (NASDAQ: ORIS) (“Oriental Rise” or the “Company”), an integrated tea supplier in mainland China, today announced that its operating subsidiary Fujian Mindong Hong Tea Industry Technology Co., Ltd. (“Mindong Hong”) has entered into a strategic cooperation agreement with Shandong Yiyang Zhongji New Energy Co., Ltd. (“Zhongji New Energy”), a renewable energy developer, to explore the deployment of solar photovoltaic power generation systems within the Company’s tea plantation bases. The collaboration is designed to evaluate the integration of agriculture and renewable energy infrastructure, a model often referred to as “agro-photovoltaic” development, which enables solar power generation while maintaining agricultural cultivation activities. Under the...

$12 Million of Tranche Warrants Potential Financing Within One Year From Closing SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses. In connection with the offering, the Company sold 12,094,631 shares of common stock (or pre-funded warrants in lieu thereof) Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,631 shares of common stock, and Series L warrants to purchase...

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.htmlMELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed. Key findings include:Tolerability profile supported by dosimetry and low-grade non-hematologic events. Lesion dosimetry indicates no difference in absorbed dose...

BIRMINGHAM, Ala., March 09, 2026 (GLOBE NEWSWIRE) — Diversified Energy Company (NYSE: DEC; LSE: DEC) (“Diversified” or the “Company”), today announced the pricing of the previously announced underwritten public offering (the “Secondary Offering”) by certain funds or entities managed by an affiliate of EIG (collectively, the “Selling Stockholder”) of 7,501,585 shares of Diversified’s common stock, par value $0.01 per share (the “common stock”), which represents all remaining holdings of the Selling Stockholder, at a price to the public of $14.45 per share. Subject to the completion of the Secondary Offering, Diversified has agreed to purchase from the underwriter 3,750,000 shares of common stock at a price per share equal to the price per share paid by the underwriter to the Selling Stockholder in the Secondary Offering (the “repurchase”). Diversified...

**NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES** SASKATOON, Saskatchewan, March 09, 2026 (GLOBE NEWSWIRE) — MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FSE: 89N) (“MAX Power” or the “Company”) is pleased to announce a listed issuer financing exemption private placement offering (the “Offering”) for minimum gross proceeds of C$4,000,000 and maximum of up to C$20,000,000. The Offering comprises 15,384,615 units of the Company (each, a “Unit”) at a price of C$1.30 per Unit (the “Issue Price”) and is led by Hampton Securities Limited as the lead agent and sole bookrunner (the “Agent”) on a commercially reasonable efforts basis. Net proceeds will be used for: 1) An ongoing program of analytical testing, resource modeling, and resource estimation of the Lawson Natural Hydrogen...

Vancouver, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) — MegaWatt Lithium and Battery Metals Corp. (CSE:MEGA) (FSE: WR20) (OTCQB: WALRF) (the “Company“, “MegaWatt Metals” or “MegaWatt”) announces that, at the annual general meeting of shareholders of the Company held on February 19, 2026, the shareholders approved, among other things, the consolidation of the common shares in the capital of the Company (the “Shares”) on the basis of one (1) post‑consolidation Share for a minimum of ten (10) pre-consolidation Shares, with the exact consolidation ratio to be determined by the board of directors of the Company. The Company intends to consolidate the Shares on the basis of one (1) post-consolidation Share for every twelve (12) pre-consolidation Shares (the “Consolidation”). The Company currently has 37,250,400...

GUADALAJARA, Mexico, March 09, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces the following: Pursuant to a resolution adopted by the Board of Directors at its meeting held on February 23, 2026, and in accordance with Articles 180, 181 and other applicable articles of the Mexican General Corporations Law, as well as Article Thirty-Fifth of the Company’s bylaws, GAP invite its shareholders to the Annual Ordinary General Shareholders’ Meeting, to be held at 12:00 p.m. on April 22, 2026, at Midtown Ballroom 3, 3rd floor of the Hilton Midtown Hotel, located at Av. López Mateos 2405-300, Col. Italia Providencia, C.P. 44648, Guadalajara, Jalisco, Mexico, in accordance with the following: ANNUAL ORDINARY GENERAL SHAREHOLDERS’ MEETINGMEETING AGENDAIn compliance...

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) announced today that it will be presenting at the Sidoti Small Cap Conference at 3:15 EST on Thursday March 19, 2026. Register here to attend the virtual event: https://sidoti.zoom.us/webinar/register/WN_YCIRIrUhQBuEB2r6HTcp5A. About Itafos Itafos is a phosphate and specialty fertilizer company with businesses and projects spanning three continents:Conda – a vertically integrated phosphate fertilizer business located in Idaho, US, with the following production capacity:approximately 550kt per year of MAP, MAP+, SPA, merchant grade phosphoric acid (“MGA”) and APP approximately 27kt per year of hydrofluorosilicic acid (“HFSA”)Arraias – a vertically integrated phosphate fertilizer business located in Tocantins, Brazil,...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectivelyMINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) PIK3CA WT advanced breast cancer (“ABC”), following...